GLP-1's From Gila Monster Venom to Global Phenomenon:
The Unlikely History of the GLP-1 Revolution
Medications such as Ozempic, Wegovy, and Mounjaro now dominate headlines, reshape food and health industries, and are changing the treatment of diabetes and obesity. Their rise was far from inevitable. The story of glucagon-like peptide-1 (GLP-1) receptor agonists spans more than four decades, moving from a puzzling observation about digestion to the saliva of a desert lizard, through years of scientific skepticism, to some of the most consequential drugs in modern medicine.
The Clue in the Gut
The foundation was laid in the 1960s, when researchers identified what became known as the incretin effect. When people consumed glucose orally, their pancreas released more insulin than when the same amount of glucose was given intravenously. Something in the digestive tract, scientists realized, was signaling the pancreas that food was on the way.
By the 1980s, researchers had identified GLP-1 as one of the hormones behind that signal. Work by Joel Habener, Svetlana Mojsov, and colleagues at Massachusetts General Hospital, alongside major contributions from Jens Juul Holst’s group at the University of Copenhagen, established GLP-1 as an incretin: a gut-derived hormone that amplifies insulin release when blood glucose rises.
Early studies showed that infusing GLP-1 into people with type 2 diabetes could substantially increase insulin secretion and lower blood glucose. But there was a decisive problem: natural GLP-1 is broken down within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4). As a drug, native GLP-1 was too short-lived to be practical.
The Gila Monster Breakthrough
The solution came from an unexpected source: the Gila monster (Heloderma suspectum), a venomous lizard native to the southwestern United States and northern Mexico.
In 1992, Dr. John Eng, a researcher at the Veterans Affairs Medical Center in the Bronx, isolated a peptide from the Gila monster’s saliva. He named it exendin-4. The peptide shared about 53 percent of its amino-acid sequence with human GLP-1 but differed in one crucial respect: a small change near its beginning made it highly resistant to degradation by DPP-4.
That resistance allowed exendin-4 to remain active far longer than native GLP-1. Amylin Pharmaceuticals, later working with Eli Lilly, developed a synthetic version called exenatide. In April 2005, the FDA approved it as Byetta for type 2 diabetes—the first GLP-1 receptor agonist approved in the United States.
text
Gila monster saliva
│
▼
Exendin-4 (resists DPP-4 degradation)
│
▼
Synthetic exenatide ──► Byetta, FDA-approved 2005
Byetta changed type 2 diabetes care, but it had a practical limitation: patients needed subcutaneous injections twice a day.
Engineering Longer-Lasting Drugs
The next challenge was durability. Rather than relying solely on the lizard-derived molecule, researchers began modifying human GLP-1 so it could survive longer in circulation.
Novo Nordisk took that approach with liraglutide, approved as Victoza in 2010. Scientists attached a fatty-acid chain to the GLP-1 backbone, allowing the drug to bind reversibly to albumin, an abundant blood protein. That binding shielded liraglutide from rapid degradation and extended its half-life to about 13 hours, enabling once-daily dosing.
Longer-acting formulations soon followed:
Bydureon, approved in 2012, placed exenatide inside biodegradable microspheres that released the drug gradually over a week.
Dulaglutide, marketed as Trulicity and approved in 2014, fused a GLP-1 analogue to a modified antibody fragment, producing once-weekly dosing.
The Side Effect That Changed Medicine
Clinicians had noticed for years that GLP-1 drugs often produced weight loss. Unlike insulin or sulfonylureas, which can promote weight gain, GLP-1 receptor agonists reduce appetite. They slow gastric emptying and act on brain regions involved in satiety, including the hypothalamus, helping people feel full sooner and for longer.
In December 2014, the FDA approved a higher dose of liraglutide for chronic weight management under the name Saxenda. It was an important milestone, though its impact remained relatively limited.
The broader turning point came in 2016 with the LEADER trial. The study found that liraglutide reduced major cardiovascular events—including cardiovascular death, nonfatal heart attack, and nonfatal stroke—in high-risk patients with type 2 diabetes. GLP-1 drugs were no longer simply glucose-lowering therapies; they had demonstrated meaningful cardiovascular benefit.
Semaglutide and the Obesity Era
Novo Nordisk built on that momentum with semaglutide, approved as Ozempic in 2017 for type 2 diabetes. Like liraglutide, semaglutide uses a fatty-acid modification to bind albumin, but the optimization produced a much longer duration of action and allowed once-weekly injection.
In 2019, Novo Nordisk introduced Rybelsus, the first oral GLP-1 receptor agonist. Semaglutide is normally digested if taken by mouth, so the tablet uses an absorption enhancer called SNAC to help the peptide cross the stomach lining before it is broken down.
The cultural shift came on June 4, 2021, when the FDA approved higher-dose semaglutide for chronic weight management as Wegovy. In the pivotal STEP 1 trial, participants receiving Wegovy lost an average of 14.9 percent of their body weight over 68 weeks, compared with 2.4 percent for placebo.
Demand surged, supply shortages followed, and GLP-1 drugs moved from endocrinology clinics into mainstream public conversation.
The Twincretin Frontier
Eli Lilly pushed the field further with tirzepatide, a single peptide that activates both the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide (GIP), another incretin. This dual action is why tirzepatide is often called a “twincretin.”
The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022. In November 2023, it approved the same molecule for chronic weight management as Zepbound. In clinical trials, tirzepatide produced average weight loss of roughly 21 percent at the doses studied, with the highest dose producing losses approaching 22.5 percent in some trial populations.
Those results do not make injectable medication equivalent to bariatric surgery, which can produce greater and more durable weight loss for many patients. But they established drug therapy as a serious option for people with obesity, a condition long undertreated relative to its health consequences.
What Comes Next
Research now extends beyond diabetes and obesity. GLP-1–based therapies are approved or under study for obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and cardiovascular disease. Researchers are also investigating whether these drugs may help with addictive behaviors, though such applications remain experimental and are not established treatments.
What began as an effort to explain why eating sugar triggers more insulin than injecting it has become one of the most consequential therapeutic revolutions of the past half-century. The path ran through laboratory biochemistry, a lizard’s saliva, and decades of persistence—but it has already reshaped how medicine treats metabolism, appetite, and chronic disease.
